- Home
- MQY vs FTRE Comparison
MQY vs FTRE Comparison
Compare MQY & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQY
- FTRE
- Stock Information
- Founded
- MQY 1994
- FTRE 1996
- Country
- MQY United States
- FTRE United States
- Employees
- MQY N/A
- FTRE N/A
- Industry
- MQY Investment Bankers/Brokers/Service
- FTRE Medical Specialities
- Sector
- MQY Finance
- FTRE Health Care
- Exchange
- MQY Nasdaq
- FTRE Nasdaq
- Market Cap
- MQY 776.5M
- FTRE 864.4M
- IPO Year
- MQY N/A
- FTRE N/A
- Fundamental
- Price
- MQY $11.33
- FTRE $12.72
- Analyst Decision
- MQY
- FTRE Hold
- Analyst Count
- MQY 0
- FTRE 8
- Target Price
- MQY N/A
- FTRE $11.64
- AVG Volume (30 Days)
- MQY 184.8K
- FTRE 1.4M
- Earning Date
- MQY 01-01-0001
- FTRE 11-05-2025
- Dividend Yield
- MQY 4.73%
- FTRE N/A
- EPS Growth
- MQY N/A
- FTRE N/A
- EPS
- MQY N/A
- FTRE N/A
- Revenue
- MQY N/A
- FTRE $2,759,900,000.00
- Revenue This Year
- MQY N/A
- FTRE $0.47
- Revenue Next Year
- MQY N/A
- FTRE N/A
- P/E Ratio
- MQY N/A
- FTRE N/A
- Revenue Growth
- MQY N/A
- FTRE 1.88
- 52 Week Low
- MQY $9.82
- FTRE $3.97
- 52 Week High
- MQY $12.52
- FTRE $25.05
- Technical
- Relative Strength Index (RSI)
- MQY 36.84
- FTRE 64.57
- Support Level
- MQY $11.16
- FTRE $9.87
- Resistance Level
- MQY $11.50
- FTRE $10.70
- Average True Range (ATR)
- MQY 0.08
- FTRE 1.00
- MACD
- MQY -0.03
- FTRE 0.12
- Stochastic Oscillator
- MQY 38.04
- FTRE 81.17
About MQY Blackrock MuniYield Quality Fund Inc.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.